
Ascletis’ oral GLP-1RA shows weight loss potential in early trial
Ascletis has announced its oral glucagon-like peptide-1 receptor agonist (GLP-1RA) has achieved early weight loss in a Phase Ib trial and is now preparing to progress to a Phase IIa study. The China-based biotech’s once-daily tablet ASC30 demonstrated a …